Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOUBLE PRO-TECT Alport
2023-508502-18-00Phase 3Authorised
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alport syndrome and chronic kidney disease (CKD) comparing Dapagliflozin (Forxiga) arm with Placebo arm (2 arms). Primary endpoint: Primary: Change in log-transformed UACR at week 48. Planned start Feb 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
Alport syndromechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-508502-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508502-18-00.